159 research outputs found
Supplemental Material, sj-tiff-1-cpt-10.1177_10742484221074585 - The Association of Alanine Aminotransferase Levels With Myocardial Perfusion Imaging and Cardiovascular Morbidity
No full textSupplemental Material, sj-tiff-1-cpt-10.1177_10742484221074585 for The Association of Alanine Aminotransferase Levels With Myocardial Perfusion Imaging and Cardiovascular Morbidity by David Yardeni, Ronen Toledano, Victor Novack, Aryeh Shalev, Arik Wolak, Yaron Rotman and Ohad Etzion in Journal of Cardiovascular Pharmacology and Therapeutics</p
« Problème ethnique », par le professeur Yaron Tsur. Traduction commentée par Yann Scioldo-Zürcher Levi
No full textThis article is a translation from Hebrew into French of the paper, famous among Israeli historians, “Ethnic Problem” by Professor Yaron Tsur. Looking at the first Jewish ethnic riots that took place in 1959 in the city of Haïfa, the author details both the chronology that led to the Eastern migrants imposing themselves in the political landscape of the State, but also the social-political processes that that had, until then, forced them to live on the margins of Israeli society. This annotated translation is aimed at readers interested in Israeli Area Studies, but also for those who interest in the way populations are “structured” by one State created in the second half of the twentieth centur
Supplemental Material, sj-tiff-2-cpt-10.1177_10742484221074585 - The Association of Alanine Aminotransferase Levels With Myocardial Perfusion Imaging and Cardiovascular Morbidity
No full textSupplemental Material, sj-tiff-2-cpt-10.1177_10742484221074585 for The Association of Alanine Aminotransferase Levels With Myocardial Perfusion Imaging and Cardiovascular Morbidity by David Yardeni, Ronen Toledano, Victor Novack, Aryeh Shalev, Arik Wolak, Yaron Rotman and Ohad Etzion in Journal of Cardiovascular Pharmacology and Therapeutics</p
Recommended from our members
Capitalism vs Socialism Debate
No full textWatch Yaron Brook - Chairman of the Board, Ayn Rand Institute - and Bhaskar Sunkara - Author of “The Socialist Manifesto: The Case for Radical Politics in an Era of Extreme Inequality”- debating about the merits and prospects of Capitalism and Socialism.Salem Cente
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
No full textGiven the high prevalence and rising incidence of non-alcoholic fatty liver disease (NAFLD), the absence of approved therapies is striking. Although the mainstay of treatment of NAFLD is weight loss, it is hard to maintain, prompting the need for pharmacotherapy as well. A greater understanding of disease pathogenesis in recent years was followed by development of new classes of medications, as well as potential repurposing of currently available agents. NAFLD therapies target four main pathways. The dominant approach is targeting hepatic fat accumulation and the resultant metabolic stress. Medications in this group include peroxisome proliferator-activator receptor agonists (eg, pioglitazone, elafibranor, saroglitazar), medications targeting the bile acid-farnesoid X receptor axis (obeticholic acid), inhibitors of de novo lipogenesis (aramchol, NDI-010976), incretins (liraglutide) and fibroblast growth factor (FGF)-21 or FGF-19 analogues. A second approach is targeting the oxidative stress, inflammation and injury that follow the metabolic stress. Medications from this group include antioxidants (vitamin E), medications with a target in the tumour necrosis factor α pathway (emricasan, pentoxifylline) and immune modulators (amlexanox, cenicriviroc). A third group has a target in the gut, including antiobesity agents such as orlistat or gut microbiome modulators (IMM-124e, faecal microbial transplant, solithromycin). Finally, as the ongoing injury leads to fibrosis, the harbinger of liver-related morbidity and mortality, antifibrotics (simtuzumab and GR-MD-02) will be an important element of therapy. It is very likely that in the next few years several medications will be available to clinicians treating patients with NAFLD across the entire spectrum of disease
Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus—authors' response
No full textWhat if Prometheus had steatosis? Potential use of FGF19 to promote regeneration of the fatty liver
No full textCoinfection with Hepatitis C Virus and Human Immunodeficiency Virus: Virological, Immunological, and Clinical Outcomes
No full text- …
